文献速递骨软组织肉瘤与黑色素瘤

个性化反应导向手术与辅助治疗对III期黑色素瘤新辅助免疫治疗后生存的影响:PRADO与OpACIN-neo的3年数据比较

Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
PubMed 文献 · Eur J Cancer · 2024-11-19

PRADO与OpACIN-neo两项2期试验的3年数据事后描述性比较显示,达到主要病理缓解(MPR)的患者省略治疗性淋巴结清扫(TLND)与未省略者3年无复发生存(RFS)和无远处转移生存(DMFS)无显著差异;无病理缓解(pNR)患者接受辅助全身治疗者3年RFS和DMFS数值上高于未接受者,但未达统计学显著。

要点

  • MPR患者省略TLND与未省略者3年RFS为93%对96%(log-rank p=0.47),DMFS为98%对96%(log-rank p=0.49),无显著差异。
  • pNR患者接受辅助全身治疗者3年RFS为64%,未接受者为35%(log-rank p=0.10),未达统计学显著。
  • pNR患者接受辅助全身治疗者3年DMFS为70%,未接受者为52%(log-rank p=0.24),未达统计学显著。

核心结论

  • 数据提示多数达到MPR的患者可安全省略TLND和辅助治疗,而pNR患者TLND后辅助全身治疗似乎改善RFS和DMFS。
  • 结果具有假设生成性,需进一步验证,但为个性化新辅助免疫治疗策略提供了潜在基础。

研究设计与样本

  • PRADO与OpACIN-neo均为评估伊匹木单抗联合纳武利尤单抗新辅助治疗III期黑色素瘤的2期研究。
  • OpACIN-neo中所有患者接受治疗性淋巴结清扫(TLND)且无后续辅助治疗。
  • PRADO采用反应导向策略:达到主要病理缓解(MPR)者省略TLND和辅助治疗,无病理缓解(pNR)者接受TLND和辅助治疗。
  • 本文为两项研究3年生存结局的描述性事后比较。

主要发现

  • MPR患者中,未接受TLND者3年RFS为93%,接受TLND者为96%(log-rank p=0.47)。
  • MPR患者中,未接受TLND者3年DMFS为98%,接受TLND者为96%(log-rank p=0.49)。
  • pNR患者中,接受辅助全身治疗者3年RFS为64%,未接受者为35%(log-rank p=0.10)。
  • pNR患者中,接受辅助全身治疗者3年DMFS为70%,未接受者为52%(log-rank p=0.24)。

临床怎么用

  • 原文未据此给出推荐,仅指出数据提示多数MPR患者可安全省略TLND和辅助治疗,pNR患者TLND后辅助全身治疗似乎改善RFS和DMFS。

局限性

  • 原文自述结果为假设生成性,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, response-directed treatment strategies. METHODS: The OpACIN-neo and PRADO trials were phase 2 studies evaluating neoadjuvant treatment with ipilimumab and nivolumab in stage III melanoma. In OpACIN-neo, all patients underwent therapeutic lymph node dissection (TLND) without subsequent adjuvant therapy. In contrast, PRADO explored a response- directed strategy, where patients achieving a major pathologic response (MPR) omitted TLND and adjuvant therapy, while those without a pathologic response (pNR) received TLND and adjuvant therapy. Here, we provide a descriptive post-hoc comparison of 3-year survival outcomes between the non-personalized approach in OpACIN-neo and the response-directed approach in PRADO. RESULTS: For patients who achieved an MPR, the 3-year recurrence-free survival (RFS) was 93 % for those without TLND versus 96 % for those with TLND (log-rank p = 0.47), and distant metastasis-free survival (DMFS) was 98 % compared to 96 % (log-rank p = 0.49), respectively. For patients with pNR, 3-year RFS rates were 64 % for those receiving adjuvant systemic therapy and 35 % for patients without (log-rank p = 0.10). DMFS rates were 70 % versus 52 % (log-rank p = 0.24), respectively. CONCLUSIONS: These data suggest that TLND and adjuvant therapy may be safely omitted in most patients achieving an MPR, while adjuvant systemic therapy following TLND appears to improve RFS and DMFS in patients with pNR. Although these results are hypothesis-generating and require further validation, they offer a potential foundation for developing personalized neoadjuvant immunotherapy approaches.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Reijers ILM, Menzies AM, Lopez-Yurda M, et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer. 2024. PMID: 39602990. doi:10.1016/j.ejca.2024.115141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。